# Efficacy of the WeCareAdvisor:  An Online Tool to Help Caregivers Manage Behavioral and Psychological Symptoms in Persons with Dementia

> **NIH NIH R01** · DREXEL UNIVERSITY · 2021 · $754,564

## Abstract

Behavioral and psychological symptoms (agitation, aggression, among many others; aka BPSD) are hallmarks
of Alzheimer's disease and related dementias (ADRD). BPSD dominate disease presentation, occur across
etiologies and disease trajectories, and have significant negative consequences for persons with dementia,
family members, and society at-large. Although there are no FDA approved medications to treat BPSD,
psychotropic medications (including anti-psychotics) are commonly used with limited efficacy and high risk.
Nonpharmacologic strategies are considered first-line treatments and have proven efficacy, but families have
little knowledge of and access to strategies and are left on their own to manage BPSD. In response, we
developed an easy-to-use, web-based platform, WeCareAdvisor, through a previously funded NINR grant (R01
NR014200) for use by family caregivers. The tool provides caregivers with knowledge about dementia, daily
tips, and a systematic approach for describing, investigating, creating and evaluating strategies using an
approach we developed (DICE) that systematically guides selection of strategies to match symptom
presentation. Our pilot randomized study (N=57; NIA-Stage 1) compared an initial treatment group to a 1-
month waitlist control with caregivers receiving weekly telephone calls and emails encouraging tool use. This
pilot demonstrated proof-of-concept with 100% of caregivers using the tool. After 1 month of use, both the
initial treatment and the waitlist control groups showed significant within group benefits in caregiver (distress,
confidence) and BPSD (frequency and severity) outcomes. Additionally, there was significant improvement in
caregiver distress in the initial treatment group as compared to the waitlist group. Unclear, is whether prompts
were necessary for tool use and/or to derive benefit. In response to PAR-18-027, we propose to test the
efficacy of WeCareAdvisor (NIA - Stage II) and tool utilization in 326 diverse caregivers using a two-group,
randomized design; caregivers will be assigned to immediate treatment or 3-month waitlist control groups. Our
specific aims are to test: 1) Short-term efficacy (1-month) of WeCareAdvisor on caregiver distress, confidence
managing BPSD, or BPSD frequency and severity; 2) Longer-term efficacy (3-months) of WeCareAdvisor on
caregiver distress, confidence managing BPSD, or BPSD frequency and severity. We will also examine
whether the waitlist control group demonstrates similar benefits after using the tool over a 3-month exposure;
and 3) Tool utilization and outcomes using different reminders (telephone + email or email only). We will also
evaluate whether tool utilization is sustained without prompts in months 3-6 for the initial treatment group.
Exploratory aims will examine frequency of use of tool components, impact on psychotropic medication use,
function, and other outcomes; and mediator (theoretically-derived variables), and moderator (race, relationship)
effects....

## Key facts

- **NIH application ID:** 10247666
- **Project number:** 5R01AG061116-03
- **Recipient organization:** DREXEL UNIVERSITY
- **Principal Investigator:** Laura N. Gitlin
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $754,564
- **Award type:** 5
- **Project period:** 2019-08-01 → 2024-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10247666

## Citation

> US National Institutes of Health, RePORTER application 10247666, Efficacy of the WeCareAdvisor:  An Online Tool to Help Caregivers Manage Behavioral and Psychological Symptoms in Persons with Dementia (5R01AG061116-03). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10247666. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*